<DOC>
	<DOCNO>NCT00805493</DOCNO>
	<brief_summary>Pediatric Bipolar Disorder ( BD ) uncommon child . Its symptom include period manic behavior ( overly happy giddy , feel grandiose , feel decrease need sleep , much energy , move usual , talk fast , speeded-up thought symptom ) . Sometimes also depression ( extreme feeling sadness irritability , take pleasure thing , even one use enjoyable , feel worthless guilty , sleep much trouble get stay asleep , feel slow restless , wish dead suicidal idea , symptom ) . Pediatric BD often difficult treat ; child may respond partially medication available many side effect tolerate . Riluzole medication think work brain chemical call glutamate may involve symptom depression BD . Previous research study show riluzole may help adults BD depression adult depression , anxiety disorder , obsessive-compulsive disorder . Riluzole may also helpful child obsessive-compulsive disorder . However , never give child BD . This study evaluate effectiveness riluzole 80 patient 9 17 year age BD symptom anxiety . Participants must try least two medication effective . The study consist four phase carry 4 5 month . Most child inpatient Pediatric Behavioral Health Unit least part study . In Phase 1 , patient undergo blood urine test , gradually taper medication . The duration phase depend medication patient receive start study . In Phase 2 , patient remain medication 1 week . Throughout time , patient monitor carefully medication restart need . In Phase 3 , last 8 week , patient assign randomly receive riluzole placebo . Those receive riluzole dose adjust need . Patients family inform drug end phase . Patients improved riluzole may continue receive NIH 1 month prepare discharge study . Patients receive placebo improve , receive riluzole improve , treat standard medication appropriate prepared discharge study . Phase 4 patient receive placebo improve . They give chance try riluzole 8 week , effective , continue additional 4 week prepare discharge study . Patients able receive riluzole National Institutes Health completion study . However , child 's doctor may able prescribe riluzole off-label use . Most patient admit Pediatric Behavioral Health Unit National Institutes Health Clinical Center medication withdrawal part study ( Phases 1 2 ) . From Phase 3 , patient may participate inpatient , outpatient , day treatment , depend best interest . All participant study invite also enroll National Institute Mental Health protocol 00-M-0198 , The Phenomenology Neurophysiology Affective Dysregulation In Children And Adolescents With Bipolar Disorder . Some research test protocol do medication-free period protocol .</brief_summary>
	<brief_title>Double-Blind Placebo-Controlled Trial Riluzole Pediatric Bipolar Disorder</brief_title>
	<detailed_description>OBJECTIVE : To test efficacy riluzole youth bipolar disorder STUDY POPULATION : Youth , age 9-17 , DSM-IV bipolar disorder , fail respond two adequate trial medication , one atypical antipsychotic medication , second either mood stabilizing medication second atypical antipsychotic medication . DESIGN : Medication withdrawal , follow 15-day dose stabilization phase 6-week double-blind , placebo-controlled treatment trial . The first two phase complete inpatient day treatment , third phase complete either settings outpatient . Individuals receive placebo offer 8-week open trial riluzole follow additional 4 week respond , receive riluzole placebo-controlled trial wish continue receive 4 week open treatment . Thus , patient opportunity receive total 12 week riluzole treatment . OUTCOME MEASURES : Clinical rating scale , include Pediatric Anxiety Rating Scale Clinical Global Improvement Scale</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Genetic Diseases , X-Linked</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>INCLUSION CRITERIA : Boys girl Ages 917 year age Meet DSMIV criterion bipolar disorder . The child must primary caregiver accompany trip NIMH , provide reliable history information , complete rating scale . Patients must psychiatrist provide clinical care BPD . All youth accept study must able complete selfrating form cooperate study procedure . Previous treatment failure define : 1 . Failure respond adequate trial ( adequate dose least two week ) mood stabilizer ( either lithium divalproex ) plus adequate trial ( sufficient dose adequate duration ) atypical antipsychotic ( risperidone , olanzapine , quetiapine , ziprasidone , aripiprazole ) 2 . Failure respond adequate trial ( sufficient dose adequate duration ) two atypical antipsychotic ( risperidone , olanzapine , quetiapine , ziprasidone , aripiprazole ) 3 . Evidence intolerance ( severe weight gain side effect ) mood stabilizer atypical antipsychotic agent . The child fail his/her current treatment define ( 3 meet ) : 1 . The child 's current CGAS score must less 60 . 2 . The child 's current psychiatrist must agree child 's response his/her current treatment minimal drug side effect prove problematic . According criterion , would clinically appropriate change child 's current treatment . 3 . On basis record review interview child parent , research team agree child 's response his/her current treatment minimal . Subject PARS score great equal 10 , derive total follow individual item : 3 ( overall severity anxious feeling ) , 5 ( overall avoidance ) , 6 ( interference family ) , 7 ( interference outside home ) . In addition , patient must score 3 high ( i.e. , clinical range ) least one four item note . EXCLUSION CRITERIA : I.Q . le 70 Autistic disorder severe pervasive developmental disorder ; psychosis interfere child 's capacity understand comply study procedure ; Unstable medical illness ( e.g . severe asthma ) contraindication riluzole Medical illness could cause symptom bipolar illness ( e.g . multiple sclerosis , thyroid disease ) ; Pregnancy Renal hepatic dysfunction would interfere excretion metabolism riluzole evidence increase upper limit normal BUN/creatinine , twofold elevation serum transaminase ( ALT/SGPT , AST/SGOT ) , gamma glutamate ( GGT ) , bilirubin . Documented history hypersensitivity intolerance riluzole . Substance abuse within two month study entry</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Mania</keyword>
	<keyword>Bipolar</keyword>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Bipolar Manic-Depressive Illness</keyword>
	<keyword>Bipolar Mood Disorder</keyword>
</DOC>